MX2020002976A - Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas. - Google Patents

Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas.

Info

Publication number
MX2020002976A
MX2020002976A MX2020002976A MX2020002976A MX2020002976A MX 2020002976 A MX2020002976 A MX 2020002976A MX 2020002976 A MX2020002976 A MX 2020002976A MX 2020002976 A MX2020002976 A MX 2020002976A MX 2020002976 A MX2020002976 A MX 2020002976A
Authority
MX
Mexico
Prior art keywords
antigen
staphylococcus
binding molecules
staphylococcus species
target antigen
Prior art date
Application number
MX2020002976A
Other languages
English (en)
Inventor
Peter Mason
Andrew Murphy
Karolina Meagher
Brinda Prasad
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020002976A publication Critical patent/MX2020002976A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con ciertas modalidades, la presente invención proporciona moléculas de unión a antígeno biespecíficas que comprenden un primer dominio de unión a antígeno que se une específicamente a un antígeno objetivo de la especie de Staphylococcus y un segundo dominio de unión a antígeno que se une a un componente del complemento. En ciertas modalidades, las moléculas de unión a antígeno biespecíficas de la presente invención son capaces de unirse al antígeno objetivo de la especie de Staphylococcus con una EC50 de aproximadamente 10 nM o menos, y/o pueden promover la deposición del complemento en la especie de Staphylococcus con una EC50 de aproximadamente 10nM. Los anticuerpos de la invención son útiles para tratar enfermedades en las que la inhibición o reducción del crecimiento de una especie de Staphylococcus se desee y/o sea terapéuticamente beneficiosa, por ejemplo, para tratar infecciones por estafilococos que incluyen una infección de la piel, celulitis, neumonía, meningitis, infección del tracto urinario, síndrome de choque tóxico, endocarditis, osteomielitis, bacteriemia o sepsis, o para prevenir o tratar una infección por estafilococos que se produzca como resultado de un procedimiento quirúrgico.
MX2020002976A 2017-09-29 2018-09-27 Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas. MX2020002976A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565569P 2017-09-29 2017-09-29
US201862654576P 2018-04-09 2018-04-09
PCT/US2018/053064 WO2019067682A1 (en) 2017-09-29 2018-09-27 BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING TO TARGET STAPHYLOCOCCUS ANTIGEN AND COMPONENT COMPONENT, AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020002976A true MX2020002976A (es) 2020-07-24

Family

ID=63858177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002976A MX2020002976A (es) 2017-09-29 2018-09-27 Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas.

Country Status (17)

Country Link
US (2) US10865236B2 (es)
EP (1) EP3688029A1 (es)
JP (1) JP2021500865A (es)
KR (1) KR20200058525A (es)
CN (1) CN111148758B (es)
AU (1) AU2018341587A1 (es)
BR (1) BR112020004977A2 (es)
CA (1) CA3076632A1 (es)
CL (1) CL2020000755A1 (es)
CO (1) CO2020003948A2 (es)
IL (1) IL273227A (es)
MA (1) MA50659A (es)
MX (1) MX2020002976A (es)
MY (1) MY199789A (es)
PH (1) PH12020500375A1 (es)
SG (1) SG11202001160XA (es)
WO (1) WO2019067682A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005863A (es) * 2018-11-21 2021-07-16 Regeneron Pharma Anticuerpos antiestafilococo y usos de estos.
MA54945A (fr) 2019-02-12 2021-12-22 Regeneron Pharma Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
BR112021023335A2 (pt) 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP2164869A2 (en) * 2007-05-31 2010-03-24 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting s. aureus orf0657n
EP3243527B1 (en) * 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
US20140212409A1 (en) * 2012-08-13 2014-07-31 Kyowa Hakko Kirin Co., Ltd. METHOD FOR INCREASING DEPOSITION OF COMPLEMENT C3b ON BACTERIAL SURFACE AND PHAGOCYTOSIS BY PHAGOCYTE AND A THERAPEUTIC METHOD AND A THERAPEUTIC AGENT FOR BACTERIAL INFECTIONS
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP4218409B1 (en) * 2013-03-13 2025-02-12 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
KR102777500B1 (ko) * 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도

Also Published As

Publication number Publication date
KR20200058525A (ko) 2020-05-27
PH12020500375A1 (en) 2020-12-07
WO2019067682A1 (en) 2019-04-04
BR112020004977A2 (pt) 2020-10-06
AU2018341587A1 (en) 2020-04-23
SG11202001160XA (en) 2020-03-30
EP3688029A1 (en) 2020-08-05
US20190100575A1 (en) 2019-04-04
IL273227A (en) 2020-04-30
JP2021500865A (ja) 2021-01-14
CL2020000755A1 (es) 2020-08-14
US10865236B2 (en) 2020-12-15
MY199789A (en) 2023-11-23
MA50659A (fr) 2020-08-05
US20210147519A1 (en) 2021-05-20
CN111148758A (zh) 2020-05-12
CO2020003948A2 (es) 2020-04-24
CA3076632A1 (en) 2019-04-04
CN111148758B (zh) 2022-12-09

Similar Documents

Publication Publication Date Title
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
MY208537A (en) Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
PH12020500375A1 (en) Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
CR20200467A (es) Agentes anticuerpos anti-cd25
MY197218A (en) Multispecific antigen-binding molecules and uses thereof
WO2015089073A3 (en) Compositions and methods for phagocyte delivery of anti-staphylococcal agents
WO2009140236A3 (en) Staphylococcus aureus-specific antibody preparations
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
NZ597046A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
EP3970747A3 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
TR201809128T4 (tr) Gram-pozitif bakterilere spesifik bağlanan bileşikler.
PH12021552903A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2021004114A (es) Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
MX382703B (es) ANTICUERPOS IGG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE-ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD.
NZ702282A (en) Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
MX2016004928A (es) Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus.
WO2022031885A3 (en) Il10ra binding molecules and methods of use
EA201070826A1 (ru) Антитела против pcrv
EA201990895A1 (ru) Антитела к о1 и варианты их применения
PH12021550538A1 (en) Anti-staphylococcus antibodies and uses thereof
MX2016007212A (es) Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos.
WO2022006219A3 (en) Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof
WO2016127104A3 (en) Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection